Protalix BioTherapeutics, Inc.
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $27.4M | $41.0M | $14.7M | $13.6M | $17.9M | $19.5M | $19.8M | $27.4M |
| Accounts Receivable | $16.5M | $2.9M | $8.8M | $14.4M | $9.4M | $4.7M | $2.9M | $2.2M |
| Inventory | $32.3M | $30.5M | $25.7M | $21.3M | $21.1M | $19.5M | $21.2M | $17.2M |
| Total Current Assets | $92.2M | $86.4M | $66.7M | $66.5M | $65.5M | $60.5M | $60.1M | $47.9M |
| Property, Plant & Equipment | $5.5M | $5.2M | $4.9M | $4.7M | $4.7M | $4.7M | $4.6M | $4.6M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $110.3M | $102.3M | $82.3M | $82.3M | $78.5M | $73.9M | $73.4M | $61.6M |
| Liabilities | ||||||||
| Accounts Payable | $6.5M | $4.3M | $5.3M | $5.4M | $6.7M | $4.1M | $4.5M | $19.6M |
| Total Current Liabilities | $31.4M | $27.4M | $26.5M | $21.9M | $24.1M | $24.3M | $25.6M | $24.2M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $38.9M | $35.1M | $34.1M | $29.4M | $28.6M | $28.7M | $30.2M | $29.1M |
| Stockholders' Equity | ||||||||
| Retained Earnings | — | — | $-385.0M | — | — | — | $-378.4M | — |
| Total Stockholders' Equity | $71.4M | $67.2M | $48.2M | $52.9M | $49.9M | $45.2M | $43.2M | $32.4M |